Cargando…
The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, inappropriately low serum PTH concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics,...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541614/ https://www.ncbi.nlm.nih.gov/pubmed/26052899 http://dx.doi.org/10.1210/en.2015-1269 |
_version_ | 1782386401724071936 |
---|---|
author | Hannan, Fadil M. Walls, Gerard V. Babinsky, Valerie N. Nesbit, M. Andrew Kallay, Enikö Hough, Tertius A. Fraser, William D. Cox, Roger D. Hu, Jianxin Spiegel, Allen M. Thakker, Rajesh V. |
author_facet | Hannan, Fadil M. Walls, Gerard V. Babinsky, Valerie N. Nesbit, M. Andrew Kallay, Enikö Hough, Tertius A. Fraser, William D. Cox, Roger D. Hu, Jianxin Spiegel, Allen M. Thakker, Rajesh V. |
author_sort | Hannan, Fadil M. |
collection | PubMed |
description | Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, inappropriately low serum PTH concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics, have been shown to normalize the gain-of-function associated with ADH-causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1-associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was determined by flow cytometry. NPS 2143 was also administered as a single ip bolus to wild-type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of a mouse model with an activating CaSR mutation demonstrate NPS 2143 to normalize the gain-of-function causing ADH1 and improve the hypocalcemia associated with this disorder. |
format | Online Article Text |
id | pubmed-4541614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-45416142015-09-03 The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1) Hannan, Fadil M. Walls, Gerard V. Babinsky, Valerie N. Nesbit, M. Andrew Kallay, Enikö Hough, Tertius A. Fraser, William D. Cox, Roger D. Hu, Jianxin Spiegel, Allen M. Thakker, Rajesh V. Endocrinology Original Research Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function mutations of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, inappropriately low serum PTH concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics, have been shown to normalize the gain-of-function associated with ADH-causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However, the effectiveness of calcilytic drugs for the treatment of ADH1-associated hypocalcemia remains to be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1 by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was determined by flow cytometry. NPS 2143 was also administered as a single ip bolus to wild-type and Nuf mice and plasma concentrations of calcium and PTH, and urinary calcium excretion measured. In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in Nuf mice led to significant increases in plasma calcium and PTH without elevating urinary calcium excretion. These studies of a mouse model with an activating CaSR mutation demonstrate NPS 2143 to normalize the gain-of-function causing ADH1 and improve the hypocalcemia associated with this disorder. Endocrine Society 2015-09 2015-06-08 /pmc/articles/PMC4541614/ /pubmed/26052899 http://dx.doi.org/10.1210/en.2015-1269 Text en Copyright © 2015 by the Endocrine Society This article has been published under the terms of the Creative Commons Attribution License (CC-BY; http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s). |
spellingShingle | Original Research Hannan, Fadil M. Walls, Gerard V. Babinsky, Valerie N. Nesbit, M. Andrew Kallay, Enikö Hough, Tertius A. Fraser, William D. Cox, Roger D. Hu, Jianxin Spiegel, Allen M. Thakker, Rajesh V. The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1) |
title | The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1) |
title_full | The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1) |
title_fullStr | The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1) |
title_full_unstemmed | The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1) |
title_short | The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1) |
title_sort | calcilytic agent nps 2143 rectifies hypocalcemia in a mouse model with an activating calcium-sensing receptor (casr) mutation: relevance to autosomal dominant hypocalcemia type 1 (adh1) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541614/ https://www.ncbi.nlm.nih.gov/pubmed/26052899 http://dx.doi.org/10.1210/en.2015-1269 |
work_keys_str_mv | AT hannanfadilm thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT wallsgerardv thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT babinskyvalerien thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT nesbitmandrew thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT kallayeniko thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT houghtertiusa thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT fraserwilliamd thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT coxrogerd thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT hujianxin thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT spiegelallenm thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT thakkerrajeshv thecalcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT hannanfadilm calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT wallsgerardv calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT babinskyvalerien calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT nesbitmandrew calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT kallayeniko calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT houghtertiusa calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT fraserwilliamd calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT coxrogerd calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT hujianxin calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT spiegelallenm calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 AT thakkerrajeshv calcilyticagentnps2143rectifieshypocalcemiainamousemodelwithanactivatingcalciumsensingreceptorcasrmutationrelevancetoautosomaldominanthypocalcemiatype1adh1 |